Roche suspends dosing in diabetes drug trials (Reuters, 10 September 2010)

10 Sept 2010


Adverse effects including hypertension and GI intolerability have led to Roche suspending clinical trials of its diabetes drug tapsoglutide.

Full article


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story